Get the Stockscreener App
131.28
2.40%
3.08
After Hours:
131.22
-0.06
-0.05%
Intra Cellular Therapies Inc stock is traded at $131.28, with a volume of 7.15M.
It is up +2.40% in the last 24 hours and up +3.22% over the past month.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. It maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
See More
Previous Close:
$128.20
Open:
$131.33
24h Volume:
7.15M
Relative Volume:
2.93
Market Cap:
$13.96B
Revenue:
$612.78M
Net Income/Loss:
$-86.37M
P/E Ratio:
-150.90
EPS:
-0.87
Net Cash Flow:
$-62.91M
1W Performance:
+2.11%
1M Performance:
+3.22%
6M Performance:
+79.84%
1Y Performance:
+83.63%
1-Day Range:
$131.20
$131.35
1-Week Range:
$128.04
$131.35
52-Week Range:
$63.30
$131.35
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Name
Intra Cellular Therapies Inc
Sector
Phone
(646) 440-9333
Address
135 ROUTE 202/206, BEDMINSTER, NY
Compare ITCI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
131.28 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
170.53 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.58 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.84 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.00 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jan-31-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-06-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-11-23 | Initiated | TD Cowen | Outperform |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Aug-22-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-22-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Initiated | Goldman | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-10-20 | Initiated | Goldman | Buy |
| Feb-20-20 | Initiated | Evercore ISI | Outperform |
| Jan-31-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-24-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-12-19 | Initiated | Jefferies | Buy |
| Feb-26-18 | Initiated | JP Morgan | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Nov-08-17 | Upgrade | SunTrust | Hold → Buy |
| Sep-07-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-30-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Aug-24-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Aug-23-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-02-17 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| May-02-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-01-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-29-16 | Downgrade | SunTrust | Buy → Neutral |
View All
Intra Cellular Therapies Inc Stock (ITCI) Latest News
Intra-Cellular Therapies progresses in Johnson & Johnson merger By Investing.com - Investing.com Australia
Intra-Cellular Therapies progresses in Johnson & Johnson merger - Investing.com
Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Finance
GW&K Investment Management LLC Sells 6,734 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Phocas Financial Corp. Has $241,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Equities Analysts Offer Predictions for ITCI FY2025 Earnings - MarketBeat
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 12-Month HighStill a Buy? - MarketBeat
Intra-Cellular Therapies Stock Soars to All-Time High of $128.01 - MSN
Where are the Opportunities in (ITCI) - Stock Traders Daily
Wealthspire Advisors LLC Acquires New Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
ING Groep NV Purchases Shares of 12,500 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Stock Rating Lowered by Mizuho - MarketBeat
HealthInvest Partners AB Sells 13,440 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Ieq Capital LLC - MarketBeat
New York State Common Retirement Fund Has $6.40 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High of $129 By Investing.com - Investing.com Australia
Intra-Cellular Therapies Stock Hits All-Time High of $129 - Investing.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Alberta Investment Management Corp - MarketBeat
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc.ITCI - Business Wire
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales - MSN
Needham & Company LLC Reaffirms Hold Rating for Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders - The Bakersfield Californian
Intra-Cellular Therapies Reports Strong 2024 Growth - TipRanks
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Mizuho cuts Intra-Cellular stock rating, lowers price target - Investing.com India
Mizuho Downgrades Intra-Cellular Therapies to Neutral From Outperform, Lowers Price Target to $132 From $140 - Marketscreener.com
Principal Financial Group Inc. Sells 46,750 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 52-Week HighWhat's Next? - MarketBeat
TimesSquare Capital Management LLC Increases Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular: Q4 Earnings Snapshot - CTPost
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates - MSN
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
CAPLYTA’s Strong Market Adoption Propels Its Rise as a Leading Antipsychotic Therapy | DelveInsight - GlobeNewswire
Hold Rating on Intra-Cellular Therapies Amid sNDA Progress and J&J Acquisition Prospects - TipRanks
Intra-Cellular Therapies, Inc. SEC 10-K Report - TradingView
Form 10-K Intra-Cellular Therapies For: Dec 31 - StreetInsider.com
Intra-Cellular: Q4 Earnings Snapshot -February 21, 2025 at 08:18 am EST - Marketscreener.com
Intra-Cellular Therapies Q4 Net Loss Narrows, Revenue Rises -February 21, 2025 at 08:17 am EST - Marketscreener.com
Earnings Flash (ITCI) Intra-Cellular Therapies Posts Q4 Net Loss $0.16 a Share, vs. FactSet Est of $0.07 Loss - Marketscreener.com
Intra-Cellular Therapies Reports Strong Fourth Quarter 2024 Results with 51% Increase in CAPLYTA Net Sales and FDA Review Acceptance for New Indication - Nasdaq
Earnings Flash (ITCI) Intra-Cellular Therapies Posts Q4 Revenue $199.2M, vs. FactSet Est of $193.4M - Marketscreener.com
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire Inc.
Savant Capital LLC Cuts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Update - MarketBeat
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat - MSN
StockNews.com Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Quantum Private Wealth LLC - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 1-Year HighHere's What Happened - MarketBeat
Intra Cellular Therapies Inc Stock (ITCI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intra Cellular Therapies Inc Stock (ITCI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mates Sharon | Chairman and CEO |
Dec 05 '24 |
Option Exercise |
12.73 |
51,697 |
658,103 |
1,122,026 |
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Option Exercise |
12.73 |
51,000 |
649,230 |
1,121,329 |
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Sale |
85.80 |
51,000 |
4,375,659 |
1,070,329 |
| Mates Sharon | Chairman and CEO |
Dec 05 '24 |
Sale |
84.08 |
51,697 |
4,346,842 |
1,070,329 |
3.57%
1.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):